BUSINESS COMBINATIONS - Narrative (Details) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended								6 Months Ended	0 Months Ended					0 Months Ended	11 Months Ended									3 Months Ended	0 Months Ended				0 Months Ended	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014 Office building	Jun. 30, 2014 Developed Markets	Dec. 31, 2013 Developed Markets	Jun. 30, 2014 Emerging Markets	Dec. 31, 2013 Emerging Markets	Jun. 30, 2014 Business Combinations in 2014	Jan. 23, 2014 Solta Medical, Inc.	Jan. 23, 2014 Solta Medical, Inc.	Jun. 30, 2014 Solta Medical, Inc. Developed Markets	Jun. 30, 2014 Solta Medical, Inc. Emerging Markets	Jan. 23, 2014 Solta Medical, Inc. Other (Income) Expense	Aug. 05, 2013 B&L	Jun. 30, 2014 B&L	Aug. 05, 2013 B&L	Aug. 05, 2013 B&L 9.875% Senior Notes	Jun. 30, 2014 B&L Various Vision Care Products	Jun. 30, 2014 B&L Various Pharmaceutical Products	Jun. 30, 2014 B&L Various Surgical Products	Jun. 30, 2014 B&L IPR&D	Jun. 30, 2014 B&L Developed Markets	Jun. 30, 2014 B&L Emerging Markets	Sep. 30, 2013 B&L Restructuring, Integration and Other Costs	Apr. 25, 2013 Obagi Medical Products, Inc	Apr. 25, 2013 Obagi Medical Products, Inc	Apr. 30, 2014 Eisai	Feb. 20, 2013 Eisai	Feb. 01, 2013 Natur Produkt	Mar. 31, 2013 Natur Produkt	Feb. 01, 2013 Natur Produkt	Jun. 30, 2014 Other Business Combinations	Dec. 31, 2013 Other Business Combinations
Business Combinations
Aggregate purchase price											$ 423.6		$ 292.5
Acquisition-related contingent consideration	88.9		88.9		114.5						49.1																			30.0	50.8					59.1
Per share consideration (in dollars per share)													$ 2.92																$ 24.00
Repayments of long-term debt												44.2
Charge relating to settlement of preexisting relationship																5.6
Fair value of accounts receivable											16.8							540.7																	64.5
Gross contractual amount of trade accounts receivable acquired											19.1							555.6																	68.2
Expected uncollectible of trade accounts receivable acquired											2.3							14.9																	3.7
Goodwill	9,436.3		9,436.3		9,752.1		7,067.2	7,428.7	2,369.1	2,323.4	111.7			64.0	42.9			4,358.0							3,300.0	1,100.0									233.3
Acquisition-related costs	0.6	7.9	2.1	15.8							2.6							13.4
Revenues of acquiree since acquisition date											61.9
Net earnings (loss), net of tax of acquiree since acquisition date											(15.3)
Par value per share of common stock (in dollars per share)																			$ 0.01
Enterprise value																	8,700.0
Cash consideration paid for unvested options																											4.3
Estimated fair value adjustment to inventory																		269.1
Carrying amount of long-lived asset held for sale						14.2
Acquired IPR&D											62.6							415.1			223.4	170.9	20.8												18.9
Risk-adjusted discount rate (as a percent)																								10.00%
Interest rate on debt (as a percent)																				9.875%
Deferred tax assets																		61.6
Deferred tax liability, noncurrent																		1,436.5																	148.9
Fair value of pension and other benefits liabilities																		224.2
Aggregate purchase price (less non-controlling interest)																		4,613.3																	898.1	898.1
Total fair value of consideration transferred																	4,613.3											437.1				149.9
Upfront payment																															66.5
Potential future milestone payments																															60.0
Contingent refund of purchase price																																		20.0
Refund of contingent purchase price																																	$ 20.0